Literature DB >> 30297534

Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.

Yang Xu1,2,3, Paul Taylor4, Joshua Andrade5, Beatrix Ueberheide5,6, Brian Shuch7, Peter M Glazer7, Ranjit S Bindra7, Michael F Moran4,8, W Marston Linehan9, Benjamin G Neel10,2,3.   

Abstract

: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an inherited cancer syndrome associated with a highly aggressive form of type 2 papillary renal cell carcinoma (PRCC). Germline inactivating alterations in fumarate hydratase (FH) cause HLRCC and result in elevated levels of reactive oxygen species (ROS). Recent work indicates that FH-/- PRCC cells have increased activation of ABL1, which promotes tumor growth, but how ABL1 is activated remains unclear. Given that oxidation can regulate protein-tyrosine phosphatase (PTP) catalytic activity, inactivation of an ABL-directed PTP by ROS might account for ABL1 activation in this malignancy. Our group previously developed "q-oxPTPome," a method that globally monitors the oxidation of classical PTPs. In this study, we present a refined q-oxPTPome, increasing its sensitivity by >10×. Applying q-oxPTPome to FH-deficient cell models showed that multiple PTPs were either highly oxidized (including PTPN12) or overexpressed. Highly oxidized PTPs were those with relatively high sensitivity to exogenous H2O2. Most PTP oxidation in FH-deficient cells was reversible, although nearly 40% of PTPN13 was irreversibly oxidized to the sulfonic acid state. Using substrate-trapping mutants, we mapped PTPs to their putative substrates and found that only PTPN12 could target ABL1. Furthermore, knockdown experiments identified PTPN12 as the major ABL1 phosphatase, and overexpression of PTPN12 inhibited ABL1 phosphorylation and HLRCC cell growth. These results show that ROS-induced oxidation of PTPN12 accounts for ABL1 phosphorylation in HLRCC-associated PRCC, revealing a novel mechanism for inactivating a tumor suppressor gene product and establishing a direct link between pathologic PTP oxidation and neoplastic disease. SIGNIFICANCE: This work identifies a novel mechanism of activation of the oncogenic kinase ABL1 via ROS-induced, oxidation-mediated inactivation of cognate protein tyrosine phosphatases. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30297534      PMCID: PMC6279512          DOI: 10.1158/0008-5472.CAN-18-0901

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.

Authors:  Aikseng Ooi; Jing-Chii Wong; David Petillo; Douglas Roossien; Victoria Perrier-Trudova; Douglas Whitten; Bernice Wong Hui Min; Min-Han Tan; Zhongfa Zhang; Ximing J Yang; Ming Zhou; Betty Gardie; Vincent Molinié; Stéphane Richard; Puay Hoon Tan; Bin Tean Teh; Kyle A Furge
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  Inherited susceptibility to uterine leiomyomas and renal cell cancer.

Authors:  V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.

Authors:  Nicole St-Denis; Gagan D Gupta; Zhen Yuan Lin; Beatriz Gonzalez-Badillo; Amanda O Veri; James D R Knight; Dushyandi Rajendran; Amber L Couzens; Ko W Currie; Johnny M Tkach; Sally W T Cheung; Laurence Pelletier; Anne-Claude Gingras
Journal:  Cell Rep       Date:  2016-11-22       Impact factor: 9.423

4.  Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.

Authors:  Tingting Sun; Nicola Aceto; Kristen L Meerbrey; Jessica D Kessler; Chunshui Zhou; Ilenia Migliaccio; Don X Nguyen; Natalya N Pavlova; Maria Botero; Jian Huang; Ronald J Bernardi; Earlene Schmitt; Guang Hu; Mamie Z Li; Noah Dephoure; Steven P Gygi; Mitchell Rao; Chad J Creighton; Susan G Hilsenbeck; Chad A Shaw; Donna Muzny; Richard A Gibbs; David A Wheeler; C Kent Osborne; Rachel Schiff; Mohamed Bentires-Alj; Stephen J Elledge; Thomas F Westbrook
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 5.  Regulation of protein tyrosine phosphatases by reversible oxidation.

Authors:  Arne Ostman; Jeroen Frijhoff; Asa Sandin; Frank-D Böhmer
Journal:  J Biochem       Date:  2011-08-19       Impact factor: 3.387

6.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

7.  Substrate-trapping techniques in the identification of cellular PTP targets.

Authors:  C Blanchetot; M Chagnon; N Dubé; M Hallé; M L Tremblay
Journal:  Methods       Date:  2005-01       Impact factor: 3.608

8.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

Review 9.  ROS-dependent signal transduction.

Authors:  Colleen R Reczek; Navdeep S Chandel
Journal:  Curr Opin Cell Biol       Date:  2014-10-08       Impact factor: 8.382

10.  Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.

Authors:  Julie Adam; Emine Hatipoglu; Linda O'Flaherty; Nicola Ternette; Natasha Sahgal; Helen Lockstone; Dilair Baban; Emma Nye; Gordon W Stamp; Kathryn Wolhuter; Marcus Stevens; Roman Fischer; Peter Carmeliet; Patrick H Maxwell; Chris W Pugh; Norma Frizzell; Tomoyoshi Soga; Benedikt M Kessler; Mona El-Bahrawy; Peter J Ratcliffe; Patrick J Pollard
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 38.585

View more
  7 in total

Review 1.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

2.  Activated Thiol Sepharose-based proteomic approach to quantify reversible protein oxidation.

Authors:  Yang Xu; Joshua Andrade; Beatrix Ueberheide; Benjamin G Neel
Journal:  FASEB J       Date:  2019-08-26       Impact factor: 5.191

Review 3.  Fumarate hydratase in cancer: A multifaceted tumour suppressor.

Authors:  Christina Schmidt; Marco Sciacovelli; Christian Frezza
Journal:  Semin Cell Dev Biol       Date:  2019-05-22       Impact factor: 7.727

4.  High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.

Authors:  Sören A Weidemann; Charlotte Sauer; Andreas M Luebke; Christina Möller-Koop; Stefan Steurer; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Till S Clauditz; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Christoph Fraune; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Asmus Heumann
Journal:  BMC Cancer       Date:  2019-10-12       Impact factor: 4.430

5.  Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.

Authors:  Yi Jin; Tian-Xi Wang; Hao Li; Peng Guo; Qing-Qing Wang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

6.  Progress in the correlation between PTPN12 gene expression and human tumors.

Authors:  Yu-Hu Huo; Ya-Ni Wang; Ling-Bing Meng; Ai-Li Zhang; Bin Liu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

Review 7.  Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.

Authors:  Peng Zeng; Alvin Schmaier
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.